CRDF
$1.92
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treatin...
Recent News
Cardiff Oncology Spotlights Onvansertib Data at Oppenheimer: 72% ORR in RAS-Mutant mCRC
Cardiff Oncology (NASDAQ:CRDF) used an appearance at Oppenheimer’s 36th Annual Healthcare Conference to highlight updated clinical results and its development plans for onvansertib, an oral, highly selective polo-like kinase 1 (PLK1) inhibitor being studied in RAS-mutated metastatic colorectal cance
Cardiff Oncology: Q4 Earnings Snapshot
SAN DIEGO (AP) — Cardiff Oncology, Inc. CRDF) on Tuesday reported a loss of $7.2 million in its fourth quarter. On a per-share basis, the San Diego-based company said it had a loss of 11 cents.
Cardiff Oncology (CRDF) Is Down 43.9% After Advancing Onvansertib And Reshuffling Leadership Team
Cardiff Oncology recently reported positive dose-dependent Phase 2 data for onvansertib in first-line RAS‑mutated metastatic colorectal cancer and outlined plans to move the 30 mg dose into a registrational trial, while simultaneously announcing a leadership reshuffle including a new interim CEO and the departure of its CFO as of January 27, 2026. The combination of advancing onvansertib toward potential late-stage development and installing an experienced biotech operator as interim CEO...
Cardiff Oncology Taps Interim CEO, Picks 30mg Onvansertib Regimen for 2026 Registrational mCRC Study
Cardiff Oncology (NASDAQ:CRDF) outlined a management transition and provided an updated clinical data readout for onvansertib during a company conference call focused on its ongoing Phase II CRDF-004 trial in first-line RAS-mutated metastatic colorectal cancer (mCRC). Leadership transition framed a
3 Promising Penny Stocks With Market Caps Below $600M
The U.S. stock market has recently extended its gains, with major indices like the Dow Jones and Nasdaq showing positive momentum amid eased geopolitical tensions. In such a climate, investors often look beyond the well-known giants to explore opportunities in smaller or emerging companies. Penny stocks, though sometimes seen as relics of past market eras, continue to offer intriguing possibilities for those seeking affordability and potential growth. Here, we examine three penny stocks that...